Rimiducid AP1903
Rimiducid (AP1903) 是一种化学蛋白二聚体,可与 FKBP 融合蛋白 紧密结合,同时与丰富的天然 FKBP 结合最少。Rimiducid 在表达二聚体依赖的 Fas 构建体的培养物中引发有效且剂量依赖的细胞凋亡,EC50 约为 0.1 nM。
-
货号:
TK0366 -
规格:
- 1mg
- 2mg
- 5mg
-
价格:
¥0.00
Rimiducid (AP1903) 是一种化学蛋白二聚体,可与 FKBP 融合蛋白 紧密结合,同时与丰富的天然 FKBP 结合最少。Rimiducid 在表达二聚体依赖的 Fas 构建体的培养物中引发有效且剂量依赖的细胞凋亡,EC50 约为 0.1 nM。
| CAS No. | 195514-63-7 |
| 生物活性 | Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis. |
| 分子式 | C78H98N4O20 |
| 分子量 | 1411.63 |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存条件 | Powder -20°C 3 years 4°C 2 years *该产品在溶液状态不稳定,建议您现用现配,即刻使用。 |
| 溶解性数据 | DMSO : 50 mg/mL (35.42 mM; Need ultrasonic) |
| 体内研究 | Rimiducid (AP1903; i.v.,0.01, 0.1, 1, 10, and 100 mg/kg) elicits a dose-dependent decrease in serum human GH levels, with a half-maximal effective dose of 0.4±0.1 mg/kg. |
| 体外研究 | The human fibrosarcoma line HT1080 is engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human first apoptosis signal (Fas) intracellular domain. Rimiducid (AP1903) elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC50 of ≈0.1 nM. Maximal killing occurred in the presence of 3 to 10 nM Rimiducid (AP1903), and the IC50 is approximately 0.2 nM. LV′VFas-transduced T lymphocytes expressing high levels of CD25 (top panel) are eliminated by with 66%±7.5% (n=10) efficiency. When cells are examined after CD25 expression returned to basal levels, 63%±4.7% (n=9) killing is observed after Rimiducid treatment. |
| 文献 | Nucleic Acids Res. 2020 Jan 10;48(1):e1. •Nat Chem Biol. 2021 Dec 2. •Nat Commun. 2021 Dec 8;12(1):7114. •Nat Commun. 2020 Apr 2;11(1):1625. •Genome Med. 2021 Oct 14;13(1):165. •Am J Hum Genet. 2020 Jul 2;107(1):111-123. •PLoS Pathog. 2021 Jul 16;17(7):e1009715. •Stem Cells Transl Med. 2020 Nov;9(11):1378-1388. •Int Immunopharmacol. 2020 Nov;88:106860. •Mol Ther-Meth Clin D. 2021 Mar 5. •Sci Rep. 2021 Jun 1;11(1):11407. •Sci Rep. 2019 Mar 6;9(1):3630. •bioRxiv. January 06, 2022. •Patent. US20210260125A1. •University of Minnesota. 2021 Jul. •Patent. US20200095604A1 •Patent. US20190271005A1. •Patent. US20180155717A1. |
| 纯度及产品资料 | 98% |